Bryce hall twitter12/19/2023 ![]() 7 In a previous mechanistic study comprising individuals with type 1 diabetes, empagliflozin was shown to reduce glomerular hyperfiltration, likely by reducing intraglomerular pressure. ![]() 6 Both conditions are considered core components of the pathophysiology contributing to progression of diabetic as well as nondiabetic CKD. ![]() The beneficial kidney effects associated with empagliflozin are thought to be mediated by various mechanisms, including restoration of tubuloglomerular feedback leading to a reduction in intraglomerular pressure and hyperfiltration. 2, 3 In the EMPA-REG OUTCOME Trial, empagliflozin markedly decreased the risk of clinically important cardiovascular events (in particular, the risk of cardiovascular death), and in further hypothesis-generating analyses, it delayed the progression of CKD in people with type 2 diabetes and established cardiovascular disease. 1 Although improved glycemic control and widespread use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) have contributed to an improved prognosis for patients with diabetic kidney disease, their renal and cardiovascular risks remain high, underscoring the need for novel therapeutic interventions.Įmpagliflozin, a selective sodium glucose cotransporter 2 (SGLT2) inhibitor, has been shown to reduce hyperglycemia, BP, and body weight in patients with type 2 diabetes. The prevalence of diabetic kidney disease continues to rise and is predicted to affect 200 million people around the world by 2040.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |